Anti-apoptotic BCL-2 family proteins: from regulatory networks to therapeutic targeting
Zhe Wang, Mutian Tang, Marina Konopleva · 2026
Read Anti-apoptotic BCL-2 family proteins: from regulatory networks to therapeutic targeting by Zhe Wang, Mutian Tang, Marina Konopleva (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13448827.txt.
Description
Zhe Wang and coauthors review a 2026 roundup of anti-death BCL-2 family proteins, the living factors that guard the powerhouse outer membrane against inner cell death. The review traces many-layer control spanning gene-reading factors, splicing and micro-RNAs, and protein-level tweaks that set protein steadiness and function.
Venetoclax set BCL-2 aiming as strong therapy in chronic lymph blood cancer and acute myeloid blood cancer, yet fight-back through MCL-1 boost, BCL-2 gene change, and energy rewire persists. BCL-XL blockade causes clotting-cell poison risk. MCL-1 blockers carry heart risk, so the authors survey aimed breakers, defense pairs, next-new blockers, and marker-guided picking.
Catalog record
| CREATOR | Zhe Wang, Mutian Tang, Marina Konopleva |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |